First AD

Second AD

Biomarker Testing in Early-Stage NSCLC

What do available data show regarding the impact of concurrent testing on 1L therapy in advanced NSCLC? 

Garcia-Pardo, et al. JAMA Netw Open, 2023

Please comment on turnaround time for results, time to 1L treatment.

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Video Series

Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing

Medical experts recommend that EGFR, ALK, and PD-L1 testing be performed as reflex tests for patients with early-stage non-small cell lung cancer to inform personalized treatment strategies. 